RS ¹ÙÀÌ·¯½º ¿¹¹æ¾à : 8°³ ½ÃÀå ÀǾàǰ ¿¹Ãø°ú ½ÃÀå ºÐ¼® - ¾÷µ¥ÀÌÆ®
Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update
»óǰÄÚµå : 1795092
¸®¼­Ä¡»ç : GlobalData
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 115 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 14,995 £Ü 21,066,000
ZIP (Single User License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 29,990 £Ü 42,132,000
ZIP (Site License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ÇÑ ºÎ¼­¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 44,985 £Ü 63,199,000
ZIP (Global License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÇØ¿Ü)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

8°³ ÁÖ¿ä ½ÃÀå Àüü¿¡¼­ RSV ¿¹¹æ¾à ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 72¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2020-2030³â ¿¹Ãø ±â°£ µ¿¾È 28.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2020³â RSV ¿¹¹æ¾à ½ÃÀå ±Ô¸ð´Â 5¾ï 8,200¸¸ ´Þ·¯À̸ç, ¸ðµç ¸ÅÃâÀº AstraZeneca/AbbVieÀÇ Synagis(palivizumab)¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. Synagis´Â °íÀ§Ç豺 ¿µ¾Æ¿¡ ÀûÀÀÁõÀ» °¡Áø ´ÜŬ·ÐÇ×ü(mAb)ÀÔ´Ï´Ù. RSV ¿¹¹æ¾à ½ÃÀåÀº AstraZeneca/SanofiÀÇ Beyfortus(nirsevimab)¿Í Merck & CoÀÇ Enflonsia(clesrovimab)¶ó´Â µÎ °³ÀÇ mAb, GSKÀÇ Arexvy, PfizerÀÇ Abrysvo, ModernaÀÇ mRESVIA¶ó´Â ÃÖÃÊÀÇ RSV ¹é½ÅÀÌ Ãâ½ÃµÇ¸é¼­ ÀÌÈÄ ¸î ³â µ¿¾È Å©°Ô ¼ºÀåÇÏ°í ´Ù¾çÈ­µÇ¾ú½À´Ï´Ù. Èı⠰³¹ß ´Ü°è¿¡ ÀÖ´Â 5Á¾ÀÇ ¹é½Åµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. GSKÀÇ GSK-3888550A, AdVaccineÀÇ BARS-13, »ç³ëÇÇÀÇ SP-0256, SP-0274, SP-0125ÀÔ´Ï´Ù.

º» º¸°í¼­´Â RS ¹ÙÀÌ·¯½º ¿¹¹æ¾àÀÇ ÁÖ¿ä 8°³ ½ÃÀå(¹Ì±¹, À¯·´ 5°³±¹, ÀϺ», È£ÁÖ)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, Áúȯ °³¿ä, ¿ªÇÐ, ÇöÀç Ä¡·á ¿É¼Ç, ¹ÌÃæÁ· ¼ö¿ä¿Í ±âȸ, ¿¬±¸°³¹ß Àü·« µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå RS ¹ÙÀÌ·¯½º ¿¹¹æ¾à : ÁÖ¿ä ¿ä¾à - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦2Àå ¼Ò°³ - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦3Àå Áúȯ °³¿ä - 2024³â 11¿ù ¾÷µ¥ÀÌÆ®, 2024³â 11¿ù±îÁö »ç°Ç ±âÁØ

Á¦4Àå ¿ªÇÐ - 2021³â 8¿ù ¾÷µ¥ÀÌÆ®, 2021³â 8¿ù±îÁö »ç°Ç ±âÁØ

Á¦5Àå Áúº´ °ü¸® - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦6Àå ÇöÀç Ä¡·á ¿É¼Ç - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦7Àå ¹ÌÃæÁ· ¼ö¿ä¿Í ±âȸ Æò°¡ - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦8Àå R&D Àü·« - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦9Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡ - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦10Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼® - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦11Àå ÇöÀç¿Í ÇâÈÄ ±â¾÷ - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦12Àå ½ÃÀå Àü¸Á - 2025³â 7¿ù ¾÷µ¥ÀÌÆ®, 2025³â 7¿ù±îÁö »ç°Ç ±âÁØ

Á¦13Àå ºÎ·Ï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

RSV is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) orthopneumovirus belonging to the Pneumoviridae family. The most common clinical scenario for RSV is an upper respiratory tract infection (URTI), which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between two to three months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which on rare occasions can progress to respiratory failure or death. RSV is also an important cause of hospitalizations and deaths in elderly adults.

Across the 8MM, GlobalData expects the RSV prophylaxis market to grow at a compound annual growth rate (CAGR) of 28.6% over the 2020-30 forecast period, reaching $7.2 billion by 2030. In 2020, the RSV prophylaxis market was valued at $582M, with all sales attributable to AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody (mAb) indicated for use in high-risk infants. The RSV prophylaxis market has undergone significant growth and diversification in the following years owing to the launch of two more mAbs, AstraZeneca/Sanofi's Beyfortus (nirsevimab) and Merck &Co's Enflonsia (clesrovimab), as well as the first RSV vaccines, GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Five vaccines in late-stage development will also drive market growth. These are GSK's GSK-3888550A, AdVaccine's BARS-13, and Sanofi's SP-0256, SP-0274, and SP-0125.

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Respiratory Syncytial Virus Prophylaxis: Executive Summary - Updated July 2025, based on events up to July 2025

2 Introduction - Updated July 2025, based on events up to July 2025

3 Disease Overview - Updated Nov 2024, based on events up to Nov 2024

4 Epidemiology - Updated Aug 2021, based on events up to Aug 2021

5 Disease Management - Updated July 2025, based on events up to July 2025

6 Current Treatment Options - Updated July 2025, based on events up to July 2025

7 Unmet Needs and Opportunity Assessment - Updated July 2025, based on events up to July 2025

8 R&D Strategies - Updated July 2025, based on events up to July 2025

9 Pipeline Assessment - Updated July 2025, based on events up to July 2025

10 Pipeline Valuation Analysis - Updated July 2025, based on events up to July 2025

11 Current and Future Players - Updated July 2025, based on events up to July 2025

12 Market Outlook - Updated July 2025, based on events up to July 2025

13 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â